Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus

Article Infectious Diseases

Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study

Nicolas Margot et al.

Summary: Through in vitro and clinical assays, this study found that mutations in HIV-1 capsid protein are associated with increased resistance to Lenacapavir, but also decreased replication capacity of the mutant viruses. In the clinical trial, all participants who received Lenacapavir treatment showed a robust virological response without any detected resistance mutations.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Add to Collection

Review Immunology

Lenacapavir: a first-in-class HIV-1 capsid inhibitor

Hadas Dvory-Sobol et al.

Summary: This review summarizes the available data for lenacapavir, a novel agent that disrupts the functioning of HIV capsid protein in multiple steps of the viral life cycle. The findings indicate that lenacapavir demonstrates potent antiviral activity against HIV-1, with no preexisting resistance observed in individuals with HIV-1 regardless of treatment history. It can be administered orally or subcutaneously, and has shown high rates of virological suppression and good tolerability when used in combination with other antiretroviral agents. Ongoing studies are exploring the potential of long-acting dosing for lenacapavir in treating HIV-1 and as a standalone agent for preventing HIV-1.

CURRENT OPINION IN HIV AND AIDS (2022)

Add to Collection

Editorial Material Medicine, General & Internal

Lenacapavir effective in multidrug-resistant HIV infections

Susanne Krome

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT (2022)

Add to Collection

Article Medicine, General & Internal

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

Sorana Segal-Maurer et al.

Summary: Patients with multidrug-resistant HIV-1 infection showed greater reduction in viral load when treated with lenacapavir compared to placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Microbiology

Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes

Nicolas Margot et al.

Summary: LEN is a potent inhibitor of HIV-1 capsid and has shown strong antiviral response in mutants with Gag cleavage site mutations and resistance to other drug classes. While LEN demonstrated wild-type susceptibility, reduced susceptibility was observed for control drugs.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Medicine, General & Internal